These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15693217)

  • 1. Respiratory syncytial virus: old challenges and new approaches.
    Chávez-Bueno S; Mejías A; Jafri HS; Ramilo O
    Pediatr Ann; 2005 Jan; 34(1):62-8. PubMed ID: 15693217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
    Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for preventing respiratory syncytial virus.
    Forbes M
    Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of infections caused by respiratory syncytial virus.
    Swedish Consensus Group
    Scand J Infect Dis; 2001; 33(5):323-8. PubMed ID: 11440215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of palivizumab and emerging therapies for respiratory syncytial virus.
    Shadman KA; Wald ER
    Expert Opin Biol Ther; 2011 Nov; 11(11):1455-67. PubMed ID: 21831008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
    Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
    Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab (synagis): counting "costs" and values.
    Carter BS
    Pediatrics; 2000 Nov; 106(5):1168-9. PubMed ID: 11185071
    [No Abstract]   [Full Text] [Related]  

  • 12. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus.
    Ogra PL
    Pediatr Infect Dis J; 2000 Aug; 19(8):774-9; discussion 811-3. PubMed ID: 10959757
    [No Abstract]   [Full Text] [Related]  

  • 14. Translational sciences approach to RSV vaccine development.
    Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
    Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
    Feltes TF; Sondheimer HM
    Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A community health concern: respiratory syncytial virus and children.
    Miller S
    J Pediatr Nurs; 2010 Dec; 25(6):551-4. PubMed ID: 21035019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
    Robinson RF; Nahata MC
    Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab: where to from here?
    Georgescu G; Chemaly RF
    Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive and therapeutic strategies for respiratory syncytial virus infection.
    Vujovic O; Mills J
    Curr Opin Pharmacol; 2001 Oct; 1(5):497-503. PubMed ID: 11764776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.